公开(公告)号：US10898535B2

公开(公告)日：2021-01-26

申请号：US16567512

申请日：2019-09-11

Applicant: AMOREPACIFIC CORPORATION

Inventor： Byung Gyu Kim ,  Young-Gyu Kang ,  Soo Hyun Kim ,  Chan Woong Park ,  Hee Young Jeon

IPC: A61K36/48 ,  A61Q19/00 ,  A61K8/9789 ,  A61P21/00 ,  A61K8/96

Abstract: The present invention relates to a composition for inhibiting and preventing myopathy comprising a bean leaf extract as an active ingredient. More specifically, the composition has an effect of inhibiting the overexpression of Atrogin1 and Murf1 specifically expressed in myocyte and restoring cell activity of myocyte to inhibit and prevent muscle loss by including the extract of bean leaf at stage R6 to R8 during the growth stage of bean.

公开(公告)号：US11717012B2

公开(公告)日：2023-08-08

申请号：US17217809

申请日：2021-03-30

Applicant: AMOREPACIFIC CORPORATION

Inventor： Su Hwan Kim ,  Sangyoul Na ,  Hyun Woo Jeong ,  Wanki Kim ,  Jisung Kim ,  Chan Woong Park

IPC: A23L33/105 ,  A23D9/007 ,  A23L29/269 ,  A23L33/21

CPC classification number: A23L33/105 ,  A23D9/007 ,  A23L29/272 ,  A23L33/21

Abstract: The present disclosure relates to an emulsion composition containing ginseng seed oil and ginseng berry extract, wherein the composition is a single phase. Whereas the existing composition containing a water-soluble ingredient as a main ingredient has the problem that, when ginseng seed oil is added, formulation stability is decreased as the ginseng seed oil is separated from the water-soluble ingredient, the emulsion composition according to the present disclosure exhibits superior stability because the ginseng seed oil is uniformly mixed with the water-soluble ingredient and separation of the ginseng seed oil from the water-soluble ingredient does not occur fora long period of time.

公开(公告)号：US11096921B2

公开(公告)日：2021-08-24

申请号：US15160218

申请日：2016-05-20

Applicant: AMOREPACIFIC CORPORATION

Inventor： Byung Gyu Kim ,  Hyun Woo Jeong ,  Su Kyung Kim ,  Si Young Cho ,  Chan Woong Park ,  Dae Bang Seo ,  Wan Gi Kim ,  Sang Jun Lee

IPC: A61K31/34 ,  A61K36/258 ,  A23L33/11 ,  A23L33/105 ,  A23L2/52

Abstract: The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the SIRT 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases.

公开(公告)号：US20200000867A1

公开(公告)日：2020-01-02

申请号：US16567512

申请日：2019-09-11

Applicant: AMOREPACIFIC CORPORATION

Inventor： Byung Gyu Kim ,  Young-Gyu Kang ,  Soo Hyun Kim ,  Chan Woong Park ,  Hee Young Jeon

IPC: A61K36/48 ,  A61Q19/00 ,  A61P21/00 ,  A61K8/96

Abstract: The present invention relates to a composition for inhibiting and preventing myopathy comprising a bean leaf extract as an active ingredient. More specifically, the composition has an effect of inhibiting the overexpression of Atrogin1 and Murf1 specifically expressed in myocyte and restoring cell activity of myocyte to inhibit and prevent muscle loss by including the extract of bean leaf at stage R6 to R8 during the growth stage of bean.

公开(公告)号：US10383904B2

公开(公告)日：2019-08-20

申请号：US14779599

申请日：2014-04-02

Applicant: Amorepacific Corporation

Inventor： Chan Woong Park ,  Su Hwan Kim ,  Jeong Hwa Jang ,  Hyun Jung Shin ,  Sun Mi Kim ,  Wan Gi Kim ,  Sang Jun Lee

IPC: A61K36/258 ,  A23L33/105

Abstract: The present invention relates to a composition which improves the quality of life of women by containing a ginseng berry extract as an active ingredient, and more specifically, to a composition which promotes the general psychological and physical health of women and improving the sexual function and sex life satisfaction women.

公开(公告)号：US10342836B2

公开(公告)日：2019-07-09

申请号：US14902392

申请日：2014-06-19

Applicant: AMOREPACIFIC CORPORATION

Inventor： Su Hwan Kim ,  Chan Woong Park ,  Jeong Hwa Jang ,  Wan Gi Kim ,  Sang Jun Lee

IPC: A61K36/00 ,  A61K36/258 ,  A61K31/07 ,  A61K31/122 ,  A61K31/197 ,  A61K31/375 ,  A61K31/4415 ,  A61K31/455 ,  A61K31/51 ,  A61K31/525 ,  A61K31/704 ,  A61K33/06 ,  A61K33/26 ,  A61K33/30 ,  A23L33/105 ,  A61K31/355 ,  A61K31/519 ,  A61K33/00 ,  A61K33/42

Abstract: The present disclosure relates to a composition containing ginseng fruit extract. The present disclosure also relates to a composition for relieving premenstrual syndrome and menstrual pain, which contains ginseng fruit extract. The composition according to the present disclosure exhibits an effect of relieving or improving the symptoms of premenstrual syndrome and thus can be used as a pharmaceutical composition or a food composition.

公开(公告)号：US20150283110A1

公开(公告)日：2015-10-08

申请号：US14437802

申请日：2013-11-29

Applicant: AMOREPACIFIC CORPORATION

Inventor： Si Young Cho ,  Dae Bang Seo ,  Chan Woong Park ,  Wan Gi Kim ,  Sang Jun Lee

IPC: A61K31/34 ,  A23L1/30

CPC classification number: A61K31/34 ,  A23L33/10 ,  A23V2002/00 ,  A61K31/05 ,  A61K31/36

Abstract: The present invention relates to a composition for preventing or treating heart disease, and more particularly, to a composition for preventing or treating heart disease, comprising (+)-syringaresinol. Specifically, (+)-syringaresinol as an active ingredient may exhibit excellent effect of preventing or improving heart disease by promoting SIRT1 expression and suppressing death of cardiomyocytes induced by reactive oxygen species. Accordingly, the composition according to the present disclosure may be used to prevent, improve or treat heart diseases including cardiovascular diseases.

Abstract translation: 本发明涉及用于预防或治疗心脏病的组合物，更具体地说，涉及包含（+） - 丁香胺的心脏病预防或治疗组合物。 具体来说，作为活性成分的（+） - 丁二烯醇可以通过促进SIRT1表达并抑制由活性氧诱导的心肌细胞死亡而表现出优异的预防或改善心脏病的效果。 因此，根据本公开的组合物可用于预防，改善或治疗包括心血管疾病的心脏病。

公开(公告)号：US11642387B2

公开(公告)日：2023-05-09

申请号：US17051990

申请日：2019-04-26

Applicant: AMOREPACIFIC CORPORATION

Inventor： Donghyun Cho ,  Suhwan Kim ,  Juewon Kim ,  Chan Woong Park ,  Dae Bang Seo

IPC: A61K36/258 ,  A23L33/105 ,  A61P31/16 ,  A61K9/00 ,  A61K31/715

CPC classification number: A61K36/258 ,  A23L33/105 ,  A61K9/0053 ,  A61K31/715 ,  A61P31/16 ,  A61K2236/331

Abstract: Disclosed is a composition for preventing or inhibiting influenza virus infection, containing ginseng berry polysaccharides as active ingredients, and the ginseng berry polysaccharides exhibit an inhibitory effect on influenza virus activity or infection due to specific ingredients and structures and, specifically, have an excellent inhibitory effect on neuraminidase activity.

公开(公告)号：US20210267242A1

公开(公告)日：2021-09-02

申请号：US17165277

申请日：2021-02-02

Applicant: AMOREPACIFIC CORPORATION

Inventor： Sukyung Kim ,  Juyeon Seo ,  Jinoh Chung ,  Wanki Kim ,  Chan Woong Park ,  Jaehyun Kim ,  Hyoseung Lee

IPC: A23L27/30 ,  A23L33/22 ,  A23L33/135 ,  A23L33/125 ,  A23L29/00

Abstract: One aspect of the present disclosure relates to a granular composition containing sugar alcohols and a method for preparing the same. More specifically, according to one aspect of the present disclosure, a granular composition having a particle size of 12 mesh to 60 mesh may be prepared by introducing raw materials containing a high content of sugar alcohols containing (i) xylitol and (ii) erythritol, mannitol or a combination thereof to an extrusion molding granular, and the granular composition has a softly melting texture and has an excellent effect in user's preference and convenience in ingestion.

公开(公告)号：US10555983B2

公开(公告)日：2020-02-11

申请号：US14781146

申请日：2014-03-27

Applicant: AMOREPACIFIC CORPORATION

Inventor： Hyun Jung Shin ,  Chan Woong Park ,  Su Hwan Kim ,  Dae Bang Seo ,  Wan Gi Kim ,  Sang Jun Lee

IPC: A61K36/258 ,  A61K31/704 ,  A23L33/105 ,  A23L2/52

Abstract: Provided in the present specification is a composition for brain activation, comprising ginseng fruit extract as an active ingredient. The composition according to the present specification allows an increase in blood flow in the brain and thus has an effect of ameliorating chronic fatigue syndrome. In addition, the composition according to the present specification activates the brain, and as a result, strengthens connectivity strength between the frontal lobe and the occipital lobe and thus has an effect of improving problem-solving accuracy and reducing solving time in the area of cognitive ability. Therefore, the composition according to the present specification can be used as a pharmaceutical composition or a food composition for patients suffering from chronic fatigue syndrome.